Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for Incyte Corporation�
76.56
-0.49 (-0.64%)
Real-time:   3:18PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 75.24 - 77.13
52 week 40.30 - 80.78
Open 76.84
Vol / Avg. 910,416.00/1.43M
Mkt cap 13.01B
P/E     -
Div/yield     -
EPS -0.37
Shares 168.94M
Beta 1.07
Inst. own 96%
Feb 10, 2015
Q4 2014 Incyte Corp Earnings Release (Estimated) - 7:00AM EST - Add to calendar
Dec 11, 2014
Incyte Corp at Oppenheimer Healthcare Conference
Dec 2, 2014
Incyte Corp at Piper Jaffray Healthcare Conference
Nov 24, 2014
Incyte Corp at Brean Capital's Life Sciences Summit Conference
Nov 6, 2014
Incyte Corp at Nomura Biotechnology Conference
Oct 30, 2014
Q3 2014 Incyte Corp Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Incyte Corp Earnings Release
Sep 26, 2014
Incyte Corp at BioCentury Publications NewsMakers in the Biotech Industry - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 29.92% -23.43%
Operating margin 35.30% -4.54%
EBITD margin - 3.69%
Return on average assets 32.48% -17.32%
Return on average equity - -
Employees 481 -
CDP Score - -

Address

1801 Augustine Cut Off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company�s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. The JAK family is composed of four tyrosine kinases JAK1, JAK2, JAK3 and Tyk2 that are involved in the signaling of a number of cytokines and growth factors.

Officers and directors

Richard U. De Schutter Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Herve Hoppenot President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Julian C. Baker Independent Vice Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
James M. Daly Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Richard S. Levy M.D. Executive Vice President, Chief Drug Development and Medical Officer
Age: 56
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 71
Bio & Compensation  - Reuters
Barry Michael Ariko Independent Director
Age: 68
Bio & Compensation  - Reuters